Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Randomized Double-blind Placebo-controlled Study of Filgotinib in Biologic DMARD-IR Psoriatic Arthritis
2019-002021-29Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Filgotinib with Placebo (2 arms). Primary endpoint: ACR20 response at Week 12. Started Feb 2020; status: terminated.
02
Drugs
filgotinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2019-002021-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002021-29.